DK0988059T3 - Humane quinonreduktase-2-konjugater til ADEPT og GDEPT - Google Patents
Humane quinonreduktase-2-konjugater til ADEPT og GDEPTInfo
- Publication number
- DK0988059T3 DK0988059T3 DK98929555T DK98929555T DK0988059T3 DK 0988059 T3 DK0988059 T3 DK 0988059T3 DK 98929555 T DK98929555 T DK 98929555T DK 98929555 T DK98929555 T DK 98929555T DK 0988059 T3 DK0988059 T3 DK 0988059T3
- Authority
- DK
- Denmark
- Prior art keywords
- nqo2
- quinone reductase
- fragment
- fusion
- variant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Nanotechnology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Electrotherapy Devices (AREA)
- Percussion Or Vibration Massage (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9712370.7A GB9712370D0 (en) | 1997-06-14 | 1997-06-14 | Therapeutic systems |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0988059T3 true DK0988059T3 (da) | 2006-01-23 |
Family
ID=10814135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK98929555T DK0988059T3 (da) | 1997-06-14 | 1998-06-15 | Humane quinonreduktase-2-konjugater til ADEPT og GDEPT |
Country Status (12)
Country | Link |
---|---|
US (3) | US6867231B1 (fr) |
EP (2) | EP1468698A3 (fr) |
JP (1) | JP4272263B2 (fr) |
AT (1) | ATE311905T1 (fr) |
CA (1) | CA2292608A1 (fr) |
CY (1) | CY1105424T1 (fr) |
DE (1) | DE69832702T2 (fr) |
DK (1) | DK0988059T3 (fr) |
ES (1) | ES2257810T3 (fr) |
GB (2) | GB9712370D0 (fr) |
HK (2) | HK1041824B (fr) |
WO (1) | WO1998057662A2 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9712370D0 (en) * | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
GB9903019D0 (en) * | 1999-02-10 | 1999-03-31 | Microbiological Res Authority | Nitroreductase enzymes |
WO2001013086A2 (fr) * | 1999-08-13 | 2001-02-22 | Brandeis University | Detection d'acides nucleiques |
CN1315529A (zh) * | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人醌蛋白还原酶9和编码这种多肽的多核苷酸 |
WO2003025128A2 (fr) * | 2001-09-14 | 2003-03-27 | Duke University | Quinone reductase 2 et aldehyde deshydrogenase utilisees comme cibles therapeutiques |
GB0328314D0 (en) * | 2003-12-05 | 2004-01-07 | Univ Bath | Therapeutics |
CA2555675A1 (fr) * | 2004-02-10 | 2005-08-25 | Trustees Of Dartmouth College | Compositions de nicotinamide riboside kinase et procedes d'utilisation |
US8114626B2 (en) * | 2004-02-10 | 2012-02-14 | Trustees Of Dartmouth College | Yeast strain and method for using the same to produce nicotinamide riboside |
EP1757609B1 (fr) | 2004-04-09 | 2013-10-16 | Chugai Seiyaku Kabushiki Kaisha | Nouveau promédicament soluble dans l'eau |
US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
EP2805719A1 (fr) * | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside et analogues |
US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
GB0517957D0 (en) | 2005-09-03 | 2005-10-12 | Morvus Technology Ltd | Method of combating infection |
GB0526552D0 (en) | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
GB2442202A (en) | 2006-09-30 | 2008-04-02 | Morvus Technology Ltd | Vermin poison |
PL3174891T3 (pl) | 2014-07-24 | 2020-08-10 | W.R. Grace & Co. - Conn. | Krystaliczna postać rybozydu nikotynamidu |
CN107428791B (zh) | 2015-03-09 | 2024-05-28 | 格雷斯公司 | 烟酰胺核苷的结晶形式 |
US10280190B2 (en) * | 2015-03-16 | 2019-05-07 | Chromadex, Inc. | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions |
WO2017011788A1 (fr) * | 2015-07-15 | 2017-01-19 | Cornell University | Synthèses, activités et procédés d'utilisation de dérivés du dihydronicotinamide riboside |
CA3045876A1 (fr) | 2016-11-11 | 2018-05-17 | The Queen's University Of Belfast | Syntheses evolutives de nicotinoyle ribosides et de nicotin oyle ribosides reduits, de leurs derives modifies, de leurs analogues phosphoryles, de leurs conjugues avec de l'adenylyle dinucleotide et de nouvelles formes cristallines de ceux-ci |
US11633421B2 (en) | 2016-11-29 | 2023-04-25 | University Of Iowa Research Foundation | Use of NAD precursors for improving maternal health and/or offspring health |
US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
EP3727400A4 (fr) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | Formes cristallines de chlorure de nicotinamide riboside |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US440859A (en) * | 1890-11-18 | Wire-rope machine | ||
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
JPS5460386A (en) * | 1977-10-20 | 1979-05-15 | Fuji Photo Film Co Ltd | Photopolymerizable composition |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
LU88258I2 (fr) | 1978-12-22 | 1994-02-03 | ||
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US5087618A (en) * | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
JPS60184252A (ja) * | 1984-03-02 | 1985-09-19 | Canon Inc | 電子写真感光体 |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
GB8615701D0 (en) | 1986-06-27 | 1986-08-06 | Delta Biotechnology Ltd | Stable gene integration vector |
GB8620926D0 (en) | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
NZ225599A (en) | 1987-08-04 | 1991-09-25 | Bristol Myers Co | Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
GB8809616D0 (en) | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
JP3092811B2 (ja) | 1988-07-23 | 2000-09-25 | デルタ バイオテクノロジー リミテッド | ペプチドおよびdna配列 |
GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
GB8929097D0 (en) | 1989-12-22 | 1990-02-28 | Imp Cancer Res Tech | Mucin nucleotides |
GB9001641D0 (en) | 1990-01-24 | 1990-03-21 | Imp Cancer Res Tech | Compounds |
WO1993008288A1 (fr) | 1991-10-23 | 1993-04-29 | Cancer Research Campaign Technology Limited | Nitroreductase bacterienne pour la reduction de cb 1954 et analogues de ceux-ci en une forme cytotoxique |
GB9200415D0 (en) | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Inactivation of cytotoxic drugs |
GB9200417D0 (en) | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
GB9323008D0 (en) * | 1993-11-05 | 1994-01-05 | Connors Thomas | Improvements relating to cancer therapy |
GB9516943D0 (en) * | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
GB9524942D0 (en) | 1995-12-06 | 1996-02-07 | Aepact Ltd | Drug therapy |
EP0869818A1 (fr) * | 1995-12-29 | 1998-10-14 | AEPACT Limited | Agents cytotoxiques |
WO1998022577A1 (fr) * | 1996-11-15 | 1998-05-28 | Maria Grazia Masucci | Proteines de fusion a demi-vie allongee |
GB9624993D0 (en) | 1996-11-30 | 1997-01-15 | Aepact Ltd | Tumour therapy |
GB9712370D0 (en) * | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
-
1997
- 1997-06-14 GB GBGB9712370.7A patent/GB9712370D0/en active Pending
-
1998
- 1998-06-15 CA CA002292608A patent/CA2292608A1/fr not_active Abandoned
- 1998-06-15 DK DK98929555T patent/DK0988059T3/da active
- 1998-06-15 JP JP50395399A patent/JP4272263B2/ja not_active Expired - Fee Related
- 1998-06-15 DE DE69832702T patent/DE69832702T2/de not_active Expired - Fee Related
- 1998-06-15 EP EP04076964A patent/EP1468698A3/fr not_active Withdrawn
- 1998-06-15 AT AT98929555T patent/ATE311905T1/de not_active IP Right Cessation
- 1998-06-15 US US09/445,865 patent/US6867231B1/en not_active Expired - Fee Related
- 1998-06-15 EP EP98929555A patent/EP0988059B8/fr not_active Expired - Lifetime
- 1998-06-15 ES ES98929555T patent/ES2257810T3/es not_active Expired - Lifetime
- 1998-06-15 GB GB9928237A patent/GB2341605B/en not_active Expired - Fee Related
- 1998-06-15 WO PCT/GB1998/001731 patent/WO1998057662A2/fr active IP Right Grant
-
2000
- 2000-04-13 HK HK02103701.2A patent/HK1041824B/zh not_active IP Right Cessation
- 2000-04-13 HK HK00102240A patent/HK1023069A1/xx not_active IP Right Cessation
-
2002
- 2002-03-13 US US10/099,830 patent/US7138122B2/en not_active Expired - Fee Related
-
2006
- 2006-03-07 CY CY20061100305T patent/CY1105424T1/el unknown
- 2006-11-09 US US11/558,042 patent/US20070166296A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2257810T3 (es) | 2006-08-01 |
EP1468698A3 (fr) | 2005-03-23 |
US20070166296A1 (en) | 2007-07-19 |
HK1041824B (zh) | 2002-11-15 |
GB9712370D0 (en) | 1997-08-13 |
EP1468698A2 (fr) | 2004-10-20 |
ATE311905T1 (de) | 2005-12-15 |
EP0988059A2 (fr) | 2000-03-29 |
EP0988059B8 (fr) | 2006-03-01 |
GB2341605A8 (en) | 2000-03-28 |
US7138122B2 (en) | 2006-11-21 |
EP0988059B1 (fr) | 2005-12-07 |
GB9928237D0 (en) | 2000-01-26 |
JP2002511754A (ja) | 2002-04-16 |
US20030086933A1 (en) | 2003-05-08 |
JP4272263B2 (ja) | 2009-06-03 |
HK1023069A1 (en) | 2000-09-01 |
GB2341605B (en) | 2002-02-20 |
DE69832702D1 (de) | 2006-01-12 |
HK1041824A1 (en) | 2002-07-26 |
GB2341605A (en) | 2000-03-22 |
DE69832702T2 (de) | 2006-08-10 |
WO1998057662A3 (fr) | 1999-08-12 |
CA2292608A1 (fr) | 1998-12-23 |
US6867231B1 (en) | 2005-03-15 |
WO1998057662A2 (fr) | 1998-12-23 |
CY1105424T1 (el) | 2010-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0988059T3 (da) | Humane quinonreduktase-2-konjugater til ADEPT og GDEPT | |
DK0988060T3 (da) | Syrelabile og enzymatisk spaltelige farvestofforbindelser til diagnose med nærinfrarödt lys og til terapi | |
AU1922101A (en) | Human fgf-21 gene and gene expression products | |
PT733644E (pt) | Complexos insulinotropicos do tipo glucagina composicoes e metodos de utilizacao | |
NO302474B1 (no) | Sakarinderivater, farmasöytisk sammensetning og anvendelse derav | |
DE69942365D1 (de) | Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben | |
HK1024268A1 (en) | Method for activating human antigen presenting cells, activated human antigen presenting cells, and use of the same. | |
FI925787A (fi) | Proteolytiska enzymers sackarinderivatinhibitorer | |
EA200401622A1 (ru) | Способы лечения ангиогенеза, роста опухолей и метастазов | |
EA200401365A1 (ru) | Способы лечения илеуса | |
UA29466C2 (uk) | Фармацевтична композиція з антипухлинною активністю | |
EP1471926A4 (fr) | Compositions et methodes pour l'utilisation therapeutique d'une sequence associee au gene atonal | |
DE3775510D1 (de) | Bindungsinduzierende komposition. | |
WO1999012951A8 (fr) | Utilisations de la nicotinamide adenine dinucleotide et de ses analogues dans le traitement des affections malignes et des maladies infectieuses | |
IT1283225B1 (it) | Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle | |
NO995944L (no) | Anti-arrytmisk blanding og fremgangsmåter for behandling | |
MX9200413A (es) | Composicion farmaceutica para el tratamiento y/o diagnostico de tumores de tejido blando. | |
FI101597B1 (fi) | Menetelmä kylmäkuivatun koostumuksen valmistamiseksi käytettäväksi potilaan valodynaamisessa hoidossa tai diagnosoinnissa | |
DK2359853T3 (da) | Farmaceutiske sammensætninger og fremgangsmåder, der er anvendelige til at modulere antiogenese | |
ES2063521T3 (es) | Mezcla de sustancias con accion terapeutica constituida por compuestos de glutation y antociano. | |
ATE120447T1 (de) | Polyamin-derivate als antineoplastische mittel. | |
NO891679L (no) | Fremgangsmaate for fremstilling av 5-klor-3-klorsulfonyl-2-tiofenkarbonsyreestere. | |
FI890173A (fi) | Isoxazoler med nootropisk verkan. |